Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of May 20, 2026, FATE trades at $1.94 with a market cap of $201.65M and a P/E ratio of -1.69. FATE moved +2.38% today. Year to date, FATE is +91.61%; over the trailing twelve months it is +54.92%. Its 52-week range spans $0.66 to $3.80. Analyst consensus is buy with an average price target of $4.46. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Fate Therapeutics, Inc. (FATE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. FATE moved +2.38% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $1.94 |
| Market Cap | $201.65M |
| P/E Ratio | -1.69 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.80 |
| 52-Week Low | $0.66 |
| Volume | 962.55K |
| Avg Volume | 0 |
| Revenue (TTM) | $6.32M |
| Net Income | $-129.91M |
| Gross Margin | 0.00% |
7 analysts cover FATE: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.46.